未找到相关数据
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
被引：0
作者：
Jiang, Zefei
Sun, Tao
Wang, Xiaojia
Liu, Qiang
Yan, Min
Tong, Zhongsheng
Geng, Cuizhi
Tang, Jinhai
Yin, Yongmei
Yu, Guohua
Wang, Jingfen
Su, Wuyun
Wang, Shusen
Pan, Yueyin
Yang, Hua
机构：
[1] Fifth Med Ctr Chinese PLA Gen Hosp, Beijing, Peoples R China
[2] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[3] Zheijang Canc Hosp, Hangzhou, Peoples R China
[4] Sun Yat Sen Univ, Sun Yat sen Mem Hosp, Guangzhou, Peoples R China
[5] Affiliated Canc Hosp Zhengzhou Univ, Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[7] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[8] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[9] Weifang Peoples Hosp, Weifang, Peoples R China
[10] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[11] Inner Mongolia Med Univ, Affiliated Hosp, Hohhot, Peoples R China
[12] Sun Yet sen Univ Canc Ctr, Guangzhou, Peoples R China
[13] Anhui Prov Hosp, Hefei, Peoples R China
[14] Hebei Univ, Affiliated Hosp, Baoding, Peoples R China
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1102
引用
收藏
页数：1
相关论文